NGAM Advisors L.P. raised its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 0.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,245 shares of the biotechnology company’s stock after buying an additional 55 shares during the period. NGAM Advisors L.P.’s holdings in BioMarin Pharmaceutical were worth $1,385,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the company. Emory University increased its stake in shares of BioMarin Pharmaceutical by 3.2% in the first quarter. Emory University now owns 23,791 shares of the biotechnology company’s stock worth $2,088,000 after buying an additional 744 shares during the period. Aperio Group LLC increased its stake in shares of BioMarin Pharmaceutical by 9.7% in the second quarter. Aperio Group LLC now owns 56,491 shares of the biotechnology company’s stock worth $5,131,000 after buying an additional 5,006 shares during the period. UBS Asset Management Americas Inc. increased its stake in shares of BioMarin Pharmaceutical by 11.3% in the first quarter. UBS Asset Management Americas Inc. now owns 1,087,995 shares of the biotechnology company’s stock worth $95,504,000 after buying an additional 110,504 shares during the period. National Pension Service increased its stake in shares of BioMarin Pharmaceutical by 8.5% in the first quarter. National Pension Service now owns 147,473 shares of the biotechnology company’s stock worth $13,143,000 after buying an additional 11,552 shares during the period. Finally, William Blair Investment Management LLC increased its stake in shares of BioMarin Pharmaceutical by 1.4% in the first quarter. William Blair Investment Management LLC now owns 1,123,928 shares of the biotechnology company’s stock worth $98,658,000 after buying an additional 15,687 shares during the period. Institutional investors own 98.34% of the company’s stock.

BioMarin Pharmaceutical Inc. (BMRN) opened at 83.08 on Wednesday. BioMarin Pharmaceutical Inc. has a 12 month low of $78.42 and a 12 month high of $102.06. The firm’s market cap is $14.56 billion. The firm’s 50-day moving average price is $88.37 and its 200-day moving average price is $90.03.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.01. BioMarin Pharmaceutical had a negative return on equity of 5.77% and a negative net margin of 15.54%. The firm had revenue of $317.50 million during the quarter, compared to analysts’ expectations of $311.41 million. During the same period last year, the firm posted ($2.61) EPS. The business’s revenue was up 5.8% on a year-over-year basis. Equities research analysts predict that BioMarin Pharmaceutical Inc. will post ($0.71) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “NGAM Advisors L.P. Has $1.39 Million Stake in BioMarin Pharmaceutical Inc. (BMRN)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/ngam-advisors-l-p-has-1-39-million-stake-in-biomarin-pharmaceutical-inc-bmrn/1493050.html.

A number of equities research analysts have recently weighed in on the company. Wedbush reiterated a “neutral” rating and issued a $108.00 price target on shares of BioMarin Pharmaceutical in a report on Monday, August 7th. Deutsche Bank AG set a $105.00 price target on BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Friday, April 28th. BMO Capital Markets lowered their price target on BioMarin Pharmaceutical from $112.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, April 24th. Jefferies Group LLC reiterated a “buy” rating and issued a $116.00 price target on shares of BioMarin Pharmaceutical in a report on Monday, May 15th. Finally, J P Morgan Chase & Co reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a report on Monday, May 1st. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $110.20.

In related news, SVP Brian Mueller sold 2,671 shares of the firm’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $100.00, for a total transaction of $267,100.00. Following the completion of the sale, the senior vice president now directly owns 15,556 shares of the company’s stock, valued at approximately $1,555,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director V Bryan Lawlis sold 3,750 shares of the firm’s stock in a transaction on Friday, June 16th. The shares were sold at an average price of $90.00, for a total value of $337,500.00. Following the sale, the director now directly owns 19,660 shares of the company’s stock, valued at $1,769,400. The disclosure for this sale can be found here. Insiders have sold a total of 56,740 shares of company stock valued at $5,200,939 over the last ninety days. Insiders own 2.50% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.